OPEN Research Support

Ida Bruun Kristensen
Department of Haematology, Odense University Hospital

Projekt styring
Projekt status    Open
Data indsamlingsdatoer
Start 01.04.2021  
Slut 31.05.2029  

Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients

Short summary

In newly diagnosed transplan- ineligible multiple myeloma patients an alternating schedule of Selinexor-dexamethasone in combination with bortezomib or lenalidomide compared to standard bortezomib-lenalidomide-dexamethasone will have an increased ORR, with decreased toxicity.


Standard treatment in Scanidinavia to ND TIE patients are VRD according to SWOG (Durie, Lancet). Selinexor is a first in -calss oral XPO-inhibitor that has shown efficacy in the R/R MM settingand also a high ORR of 93% in ND MM patients in combination with lenalidomide. In order to increase efficiency to a four drug combination without increasing toxicity we will compare ORR of an alternating schedule of selinexor-bortezomib/lenalidoide and dexamethasone to a standard VRD regimen.

Description of the cohort

Newly diagnosed transplant-ineligible treatment demanding multiple myeloma patients

Data and biological material

10mL bone marrow aspirates for MRD analysis before and after induction treatment 5mL bone marrow aspirates before induction treatment for focused gene expression FACIT-Fatigue QLQ-C30 PRO-CTCAE data

Collaborating researchers and departments

Department of Clinical and Molecular Medicine, NTNU

  • Toril Holien, PhD

Haematology Pathology Research Laboratory